Aridis Pharmaceuticals Inc. (ARDS): Price and Financial Metrics

Aridis Pharmaceuticals Inc. (ARDS): $6.96

0.17 (+2.50%)

POWR Rating

Component Grades













ARDS Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ARDS is -0.12 -- better than merely 6.23% of US stocks.
  • With a price/sales ratio of 81.1, Aridis Pharmaceuticals Inc has a higher such ratio than 96.12% of stocks in our set.
  • ARDS's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 4.77% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Aridis Pharmaceuticals Inc are BLCM, RDUS, AGE, PROG, and IDXG.
  • Visit ARDS's SEC page to see the company's official filings. To visit the company's web site, go to

ARDS Price Target

For more insight on analysts targets of ARDS, see our ARDS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $17.00 Average Broker Recommendation 1.5 (Moderate Buy)

ARDS Stock Price Chart Interactive Chart >

Price chart for ARDS

ARDS Price/Volume Stats

Current price $6.96 52-week high $8.65
Prev. close $6.79 52-week low $4.70
Day low $6.67 Volume 4,511
Day high $7.00 Avg. volume 24,564
50-day MA $6.15 Dividend yield N/A
200-day MA $6.70 Market Cap 78.18M

Aridis Pharmaceuticals Inc. (ARDS) Company Bio

Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. The company was founded in 2003 and is based in San Jose, California.

ARDS Latest News Stream

Event/Time News Detail
Loading, please wait...

ARDS Latest Social Stream

Loading social stream, please wait...

View Full ARDS Social Stream

Latest ARDS News From Around the Web

Below are the latest news stories about Aridis Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARDS as an investment opportunity.

Aridis Pharmaceuticals Announces 2020 Fourth Quarter and Year-End Financial Results and Business Update

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the fourth quarter ended December 31, 2020.

Yahoo | March 30, 2021

Aridis Pharmaceuticals Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced an interview with Vu Truong, Ph.D., Chief Executive Officer will air on The RedChip Money Report® on the Bloomberg Network in the U.S. on Saturday, March 27th, at 7 p.m. local time.

Yahoo | March 26, 2021

Aridis Enters into APEX™ Licensing and Product Discovery Agreement for Zoonotic Viruses with Kermode

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an out-licensing and product discovery agreement with Kermode Biotechnologies, Inc. Kermode works on vaccines and mAbs for zoonotic viruses, which are animal viruses that have the ability to infect humans.

Yahoo | March 8, 2021

The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acceleron Pharma Inc (NASDAQ: XLRN) Akari Therapeutics PLC (NASDAQ: AKTX) Annexon Inc (NASDAQ: ANNX) Applied Molecular Transport Inc. (NASDAQ: AMTI) AxoGen, Inc (NASDAQ: AXGN) Burning Rock Biotech Ltd (NASDAQ: BNR) Celcuity Inc (NASDAQ: CELC) (announced a $20 million common stock offering) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Cerecor Inc (NASDAQ: CERC) Citius Pharmaceuticals Inc (NASDAQ: CTXR) DermTech Inc (NASDAQ: DMTK) Gemini Therapeutics Inc (NASDAQ: GMTX) Intra-Cellular Therapies Inc (NASDAQ: ITCI) (announced NDA submissions for two indications for Caplyta - as monotherapy and as adjunctive therapy with lithium or valproate for the t...

Yahoo | February 23, 2021

Aridis Pharma To Test Inhaled Antibody Cocktail In COVID-19 Variants

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has added its inhaled AR-711 monoclonal antibody with a second antibody, AR-713, designed to neutralize newly emerging COVID-19 mutated variants. The company says that the cocktail referred to as AR-712 will provide broad coverage of all known high-risk strains. Also, Aridis announced preclinical development services support from NIAID. The company is on track to initiate the program's Phase 1/2/3 trial in the second half of 2021. AR-711 is being developed as a self-administered, at-home inhaled treatment for COVID-19 patients who are not yet hospitalized. AR-711 and AR-713 are fully human immunoglobulin G1 monoclonal antibodies discovered from screening the antibody-secreting B-cells of convalescent SARS-CoV-2 virus-infected (COVID-19) patients...

Yahoo | February 23, 2021

Read More 'ARDS' Stories Here

ARDS Price Returns

1-mo 12.99%
3-mo -1.14%
6-mo 3.88%
1-year -8.18%
3-year N/A
5-year N/A
YTD 14.66%
2020 36.40%
2019 -59.87%
2018 N/A
2017 N/A
2016 N/A

Continue Researching ARDS

Want to see what other sources are saying about Aridis Pharmaceuticals Inc's financials and stock price? Try the links below:

Aridis Pharmaceuticals Inc (ARDS) Stock Price | Nasdaq
Aridis Pharmaceuticals Inc (ARDS) Stock Quote, History and News - Yahoo Finance
Aridis Pharmaceuticals Inc (ARDS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6738 seconds.